FY2022 Q3 Financial and R&D Update

ENHERTU® Clinical and Regulatory Progress HER2+ breast cancer, 2L ■Nov 2022: Approval in Japan HER2 low breast cancer, post-chemo ■Dec 2022: Recommended for approval in EU by CHMP Jan 2023: Approval in EU HER2 mutant NSCLC, 2L+ ■Dec 2022: Filing accepted in Japan ■Jan 2023: Filing accepted in EU Daiichi-Sankyo CHMP: Committee for Medicinal Products for Human Use, NSCLC: non-small cell lung cancer 22

View entire presentation